Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v7092850 http://scihub22266oqcxt.onion/10.3390/v7092850 C4584294!4584294 !26389935     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26389935 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26389935 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Viruses 2015 ; 7 (9 ): 4929-44 Nephropedia Template TP {{tp|p=26389935 |t=2015. Clinical Implications of Antiviral Resistance in Influenza |pdf=|usr=}}{{26389935 }} gab.com Text Clinical Implications of Antiviral Resistance in Influenza JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=26389935 #FOAvip Influenza is a major cause of severe respiratory infections leading to excessive hospitalizations and deaths globally; annual epidemics, pandemics, and sporadic/endemic avian virus infections occur as a result of rapid, continuous evolution of influenza viruses. Emergence of antiviral resistance is of great clinical and public health concern. Currently available antiviral treatments include four neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir), M2-inibitors (amantadine, rimantadine), and a polymerase inhibitor (favipiravir). In this review, we focus on resistance issues related to the use of neuraminidase inhibitors (NAIs). Data on primary resistance, as well as secondary resistance related to NAI exposure will be presented. Their clinical implications, detection, and novel therapeutic options undergoing clinical trials are discussed. Twit Text FOAVip Clinical Implications of Antiviral Resistance in Influenza ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=26389935 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26389935 #FOAvip English Wikipedia <ref>{{Cite pmid|26389935 }}</ref> Clinical Implications of Antiviral Resistance in Influenza #MMPMID26389935 Li TC ; Chan MC ; Lee N Viruses 2015[Sep]; 7 (9 ): 4929-44 PMID26389935 show ga Influenza is a major cause of severe respiratory infections leading to excessive hospitalizations and deaths globally; annual epidemics, pandemics, and sporadic/endemic avian virus infections occur as a result of rapid, continuous evolution of influenza viruses. Emergence of antiviral resistance is of great clinical and public health concern. Currently available antiviral treatments include four neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir), M2-inibitors (amantadine, rimantadine), and a polymerase inhibitor (favipiravir). In this review, we focus on resistance issues related to the use of neuraminidase inhibitors (NAIs). Data on primary resistance, as well as secondary resistance related to NAI exposure will be presented. Their clinical implications, detection, and novel therapeutic options undergoing clinical trials are discussed. |*Drug Resistance, Viral [MESH] |Antiviral Agents/*pharmacology/therapeutic use [MESH] |Humans [MESH] |Influenza, Human/*drug therapy/*virology [MESH] |Neuraminidase/*antagonists & inhibitors [MESH] |Orthomyxoviridae/*drug effects/enzymology [MESH]Clinical Implications of Antiviral Resistance in Influenza (epmc).pdf DeepDyve Pubget Overpricing